OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	1599
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	1394
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	1273
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	789
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	512
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	437
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	358
Efficacy and safety of infliximab in patients with autoimmune hepatitis	286
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	263
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	224
Retracted	207
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	203
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	198
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model	190
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	178
Cover Image	171
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	166
Late-Breaking Abstracts	161
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	160
Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients	156
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	156
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	155
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	151
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	151
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	146

Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	136
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	130
REPLY:	125
Reply	124
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	124
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	123
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	122
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	119
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	118
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	118
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	117
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension	117
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	116
Access to technology to support telehealth in areas without specialty care for liver disease	113
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction-associated steatosis	111
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	110
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	106
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	105
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	105
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	105
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway	104
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	102
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	101
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	100
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	99
Regulatory role and translational potential of CCL11 in liver fibrosis	98
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	97
	97
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	97
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	94
	93
Instructions to Authors	91
Letter to the editor	89
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	88
Healthy peribiliary glands are necessary for successful liver transplantation	87
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	87
Erratum	87
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	86
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	83
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	82
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	82
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	80
Letter to the Editor: Overlooking the important factor: Hypoxia	80
Reply	80
Extracellular Signal‐Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells	79
MRI‐Based Iron Phenotyping and Patient Selection for Next‐Generation Sequencing of Non–Homeostatic Iron Regulator Hemochromatosis Genes	79
REPLY:	78
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	77
In vivo imaging of calcium dynamics in zebrafish hepatocytes	77
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	76

Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	76
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	76
Letter to the Editor	76